Animal Models for Osteoporosis

被引:150
作者
Turner R.T. [1 ,2 ]
Maran A. [1 ]
Lotinun S. [1 ]
Hefferan T. [1 ]
Evans G.L. [1 ]
Zhang M. [1 ]
Sibonga J.D. [1 ]
机构
[1] Orthopedic Research, Mayo Clinic, Rochester
[2] Orthopedic Research, Mayo Clinic, Rochester, MN 55905
关键词
Aging; Bone metabolism; Dogs; Fractures; Mice; Monkeys; Rats;
D O I
10.1023/A:1010067326811
中图分类号
学科分类号
摘要
Animal models will continue to be important tools in the quest to understand the contribution of specific genes to establishment of peak bone mass and optimal bone architecture, as well as the genetic basis for a predisposition toward accelerated bone loss in the presence of co-morbidity factors such as estrogen deficiency. Existing animal models will continue to be useful for modeling changes in bone metabolism and architecture induced by well-defined local and systemic factors. However, there is a critical unfulfilled need to develop and validate better animal models to allow fruitful investigation of the interaction of the multitude of factors which precipitate senile osteoporosis. Well characterized and validated animal models that can be recommended for investigation of the etiology, prevention and treatment of several forms of osteoporosis have been listed in Table 1. Also listed are models which are provisionally recommended. These latter models have potential but are inadequately characterized, deviate significantly from the human response, require careful choice of strain or age, or are not practical for most investigators to adopt. It cannot be stressed strongly enough that the enormous potential of laboratory animals as models for osteoporosis can only be realized if great care is taken in the choice of an appropriate species, age, experimental design, and measurements. Poor choices will result in misinterpretation of results which ultimately can bring harm to patients who suffer from osteoporosis by delaying advancement of knowledge.
引用
收藏
页码:117 / 127
页数:10
相关论文
共 41 条
[1]  
Kimmel D.B., Animal models for in vivo experimentation in osteoporosis research, Osteoporosis, pp. 671-690, (1996)
[2]  
Geddes A.D., Animals models of bone disease, Principals of Bone Biology, pp. 1343-1354, (1996)
[3]  
Turner R.T., Riggs B.L., Spelsberg T.C., Skeletal effects of estrogen, Endocr Rev, 15, pp. 275-300, (1994)
[4]  
Erben R.G., Trabecular and endocortical bone surfaces in the rat: Modeling or remodeling?, Anat Rec, 246, pp. 39-46, (1996)
[5]  
Joss E.E., Sobel E.H., Zuppinger K.A., Skeletal maturation in rats with special reference to order and time of epiphyseal closure, Endocrinology, 72, (1962)
[6]  
Sibonga J.D., Zhang M., Ritman E.L., Turner R.T., Restoration of bone mass in the severely osteopenic senescent rat, J Gerontol, 55 A, 2, (2000)
[7]  
Wronski T.J., Lowry P.L., Walsh C.C., Ignaszewski L.A., Skeletal alterations in ovariectomized rats, Calcif Tissue Int, 37, pp. 324-329, (1985)
[8]  
Goulding A., Gold E., A new way to induce oestrogen-deficiency osteopenia in the rat: Comparison of the effect of surgical ovariectomy and administration of the LHRH agonist buserelin on bone resorption and composition, J Endocrinol, 121, pp. 293-298, (1989)
[9]  
Gallagher A., Chambers T.J., Tobias J.H., The estrogen antagonist ICI 182,780 reduces cancellous bone volume in female rats, Endocrinology, 133, pp. 2787-2791, (1993)
[10]  
Turner R.T., Wakley G.K., Hannon K.S., Bell N.H., Tamoxifen prevents the skeletal effects of ovarian hormone deficiency in rats, J Bone Miner Res, 2, pp. 449-456, (1987)